The stock price of Cardlytics Inc (NASDAQ: CDLX) has plunged by -5.29 when compared to previous closing price of 3.60, but the company has seen a -22.08% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-06 that Cardlytics, Inc. (CDLX) Q3 2024 Earnings Call Transcript
Is It Worth Investing in Cardlytics Inc (NASDAQ: CDLX) Right Now?
The 36-month beta value for CDLX is also noteworthy at 1.53. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CDLX is 48.29M, and at present, short sellers hold a 14.70% of that float. The average trading volume of CDLX on November 15, 2024 was 865.69K shares.
CDLX’s Market Performance
The stock of Cardlytics Inc (CDLX) has seen a -22.08% decrease in the past week, with a -13.80% drop in the past month, and a -8.71% fall in the past quarter. The volatility ratio for the week is 11.76%, and the volatility levels for the past 30 days are at 8.85% for CDLX. The simple moving average for the past 20 days is -17.27% for CDLX’s stock, with a -55.45% simple moving average for the past 200 days.
Analysts’ Opinion of CDLX
Many brokerage firms have already submitted their reports for CDLX stocks, with Evercore ISI repeating the rating for CDLX by listing it as a “In-line.” The predicted price for CDLX in the upcoming period, according to Evercore ISI is $4 based on the research report published on October 11, 2024 of the current year 2024.
Northland Capital, on the other hand, stated in their research note that they expect to see CDLX reach a price target of $5. The rating they have provided for CDLX stocks is “Market Perform” according to the report published on August 16th, 2024.
BofA Securities gave a rating of “Underperform” to CDLX, setting the target price at $3.50 in the report published on August 15th of the current year.
CDLX Trading at -8.60% from the 50-Day Moving Average
After a stumble in the market that brought CDLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.41% of loss for the given period.
Volatility was left at 8.85%, however, over the last 30 days, the volatility rate increased by 11.76%, as shares sank -13.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.15% lower at present.
During the last 5 trading sessions, CDLX fell by -21.62%, which changed the moving average for the period of 200-days by -55.17% in comparison to the 20-day moving average, which settled at $4.12. In addition, Cardlytics Inc saw -63.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDLX starting from Gupta Amit, who sale 22,607 shares at the price of $3.85 back on Oct 24 ’24. After this action, Gupta Amit now owns 178,519 shares of Cardlytics Inc, valued at $86,924 using the latest closing price.
Gupta Amit, the Officer of Cardlytics Inc, proposed sale 22,607 shares at $3.84 during a trade that took place back on Oct 24 ’24, which means that Gupta Amit is holding shares at $86,919 based on the most recent closing price.
Stock Fundamentals for CDLX
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.44 for the gross margin
The net margin for Cardlytics Inc stands at -0.94. The total capital return value is set at -0.8. Equity return is now at value -186.12, with -53.09 for asset returns.
Based on Cardlytics Inc (CDLX), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04. The debt to equity ratio resting at 3.06. The interest coverage ratio of the stock is -23.67.
Currently, EBITDA for the company is -99.0 million with net debt to EBITDA at -0.65. When we switch over and look at the enterprise to sales, we see a ratio of 1.12. The receivables turnover for the company is 2.68for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In summary, Cardlytics Inc (CDLX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
